CardioNet, Inc. Announces Highmark Medicare Services Reimbursement Reduction Regarding CPT Code 93229

CONSHOHOCKEN, Penn.--(Business Wire)--
CardioNet (Nasdaq: BEAT), announced today that on Friday, July 10, 2009, it
received a letter from Highmark Medicare Services stating effective September 1,
2009 Highmark was adjusting its reimbursement rate for MCOT services to $754 per
service. This reimbursement change affects all providers covered under CPT Code
93229.

Randy Thurman, Chairman, President and CEO of CardioNet, Inc., said, "CardioNet
strongly believes that this reduction is unjustified and will immediately pursue
with Highmark and CMS a methodology that appropriately values MCOT technology
and related services. This review with Highmark and CMS will reinforce for
Medicare the demonstrated benefit of Mobile Cardiac Outpatient Telemetry in
detecting cardiac arrhythmias and improving the health of Medicare
beneficiaries.

"We are strong proponents and supporters of the very real need to manage the
cost of healthcare. We believe that early diagnosis through innovation in
technology is fundamental to the provision of high quality health care and a
cost efficient US healthcare system. Nearly 250,000 patients have been enrolled
in MCOT to date with physicians and patients greatly benefiting from the
CardioNet MCOT technology and service. We have made it our mission at CardioNet
to educate the medical community about the value of wireless medicine in the
diagnosis and detection of disease and we will further increase our efforts to
demonstrate its potential to substantially lower costs to both patients and
payors."

CardioNet has previously indicated that while it had been aware Highmark
Medicare Services was conducting a normal review of the reimbursement rate for
MCOT, it had received no indication of any rate adjustment or the specific
timing of a Highmark decision prior to being notified on July 9, 2009. During a
July 9 communication, Highmark reported that CardioNet would receive a letter
notifying it of a change in reimbursement including the exact amount of the
change. That letter arrived July 10, 2009.

Based on the Company`s ongoing discussions with Highmark and CMS and the
Company`s desire for a re-evaluation of reimbursement that it is pursuing, but
cannot assure will be realized, the Company believes it is prudent to withdraw
previously stated 2009 guidance at this time.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely clinical
information regarding an individual's health. CardioNet's initial efforts are
focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm
disorders, with a solution that it markets as Mobile Cardiac Outpatient
TelemetryTM (MCOT). More information can be found at http://www.cardionet.com.

Forward-Looking Statements

This press release includes certain forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995 regarding, among other things, our growth prospects, the
prospects for our products and our confidence in the Company's future. These
statements may be identified by words such as "expect," "anticipate,"
"estimate," "intend," "plan," "believe," "promises" and other words and terms of
similar meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including important
factors that could delay, divert, or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. These
factors include, among other things, the potential for re-evaluation from
Highmark or the CMS, the success of our sales and marketing initiatives, our
ability to attract and retain talented executive management and sales personnel,
our ability to identify acquisition candidates, acquire them on attractive terms
and integrate their operations into our business, the commercialization of new
products, market factors, internal research and development initiatives,
partnered research and development initiatives, competitive product development,
changes in governmental regulations and legislation, changes to reimbursement
levels for our products, the continued consolidation of payors, acceptance of
our new products and services and patent protection and litigation. For further
details and a discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission, including our
latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise.

CardioNet, Inc.
Marty Galvan, 800-908-7103
Investor Relations
investorrelations@cardionet.com

Copyright Business Wire 2009